This document is one important step in a process for improving access to quality of care in family
planning by reviewing the medical eligibility criteria for selecting methods of contraception. It
updates the second edition of Improving access to quality care in family planning: medical
eligibility criteria for contraceptive use, published in 2000, and summarizes the main
recommendations of an expert Working Group meeting held at the World Health Organization,
Geneva, 21−24 October 2003. (Please see Annex 2 for the list of participants.) The Working
Group brought together 36 participants from 18 countries, including representatives of many
agencies and organizations. The document provides recommendations for appropriate medical
eligibility criteria based on the latest clinical and epidemiological data and is intended to be used
by policy-makers, family planning programme managers and the scientific community. It aims to
provide guidance to national family planning/reproductive health programmes in the preparation
of guidelines for service delivery of contraceptives. It should not be seen or used as the actual
guidelines but rather as a reference.
The document covers the following family planning methods: low-dose combined oral contraceptives (COCs), combined injectable contraceptives (CICs), combined patch (P), combined vaginal ring (R), progestogen-only pills (POPs), depot medroxyprogesterone acetate (DMPA), norethisterone enantate (NET-EN), levonorgestrel (LNG) and etonogestrel (ETG) implants, emergency contraceptive pills (ECPs), copper intrauterine devices (Cu- IUDs), levonorgestrel-releasing IUDs (LNG-IUDs), copper-IUD for emergency contraception (E-IUD), barrier methods (BARR), fertility awareness-based methods (FAB), lactational amenorrhoea method (LAM), coitus interruptus (CI), and female and male sterilization (STER).
WHO will update and add to the recommendations in this document at appropriate intervals through expert Working Group meetings every three to four years and through input from its family planning Guidelines Steering Group on an as-needed basis. These recommendations will be made available on the WHO web site (www.who.int/reproductivehealth). The web site will also provide additional information determined by WHO to be relevant to these recommendations, pending the next formal consensus Working Group meeting. Such updates may be particularly warranted for issues where the evidence base may change rapidly. WHO encourages research to address key unresolved issues for establishing medical eligibility criteria for contraceptive use. WHO also invites comments and suggestions for improving this guidance.
This document is not a formal publication of the World Health Organization (WHO), and all the rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced, and translated in part or in whole, but not for sale nor for use in conjunction with commercial purposes. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
Management of Rheumatoid Arthritis in Germany – Findings of a Claims Database Analysis Hagenmeyer EG1, Gothe H1, Höer A1, Runge C2, Häussler B11 IGES – Institute for Healthcare and Social Research GmbH, Berlin, Germany; 2Wyeth Pharma, Ltd., Muenster, GermanyFigure 3: Sick leaves and hospitalisations in patients prior to TNF-α Objectives inhibitors therapy and all enrolees with RARh
Main Number| 856-751-1331 Trading Desk | 800-486-1515 Web: www.sturdivant-co.com Email: [email protected] MORNING NOTES…8/6/2012 THE ANALYST’S DESK Kraft Foods (KFT-40.51, Not Rated, Yield 2.0%) Kraft reported that operating EPS was $0.68 versus $0.62 in the second quarter of 2011, in line with estimates. Net revenue fell 4.3%, organic revenue grew 8.3%. First